45 results on '"Chen, Chiung-Tong"'
Search Results
2. Enhanced oral bioavailability of paclitaxel by d-α-tocopheryl polyethylene glycol 400 succinate in mice
- Author
-
Ho, Pei-Yin, Yeh, Teng-Kuang, Yao, Hsien-Tsung, Lin, Heng-Liang, Wu, Hsin-Yi, Lo, Yu-Kang, Chang, Yi-Wei, Chiang, Tien-Hui, Wu, Stephen H.W., Chao, Yu-Sheng, and Chen, Chiung-Tong
- Published
- 2008
- Full Text
- View/download PDF
3. Development and validation of a liquid chromatography–tandem mass spectrometry for the determination of BPR0L075, a novel antimicrotuble agent, in rat plasma: Application to a pharmacokinetic study
- Author
-
Chang, Yi-Wei, Chen, Wei-Cheng, Lin, Ke-Ta, Chang, Ling, Yao, Hsien-Tsung, Hsieh, Hsing-Pang, Lan, Shih-Jung, Chen, Chiung-Tong, Chao, Yu-Sheng, and Yeh, Teng-Kuang
- Published
- 2007
- Full Text
- View/download PDF
4. Artificial intelligence approach fighting COVID-19 with repurposing drugs.
- Author
-
Ke, Yi-Yu, Peng, Tzu-Ting, Yeh, Teng-Kuang, Huang, Wen-Zheng, Chang, Shao-En, Wu, Szu-Huei, Hung, Hui-Chen, Hsu, Tsu-An, Lee, Shiow-Ju, Song, Jeng-Shin, Lin, Wen-Hsing, Chiang, Tung-Jung, Lin, Jiunn-Horng, Sytwu, Huey-Kang, and Chen, Chiung-Tong
- Published
- 2020
- Full Text
- View/download PDF
5. Repurposing old drugs as antiviral agents for coronaviruses.
- Author
-
Yang, Cheng-Wei, Peng, Tzu-Ting, Hsu, Hsing-Yu, Lee, Yue-Zhi, Wu, Szu-Huei, Lin, Wen-Hsing, Ke, Yi-Yu, Hsu, Tsu-An, Yeh, Teng-Kuang, Huang, Wen-Zheng, Lin, Jiunn-Horng, Sytwu, Huey-Kang, Chen, Chiung-Tong, and Lee, Shiow-Ju
- Published
- 2020
- Full Text
- View/download PDF
6. Identification of a potent 5-phenyl-thiazol-2-ylamine-based inhibitor of FLT3 with activity against drug resistance-conferring point mutations.
- Author
-
Chen, Chiung-Tong, Hsu, John T.-A., Lin, Wen-Hsing, Lu, Cheng-Tai, Yen, Shih-Chieh, Hsu, Tsu, Huang, Yu-Ling, Song, Jen-Shin, Chen, Chun-Hwa, Chou, Ling-Hui, Yen, Kuei-Jung, Chen, Ching-Ping, Kuo, Po-Chu, Huang, Chen-Lung, Liu, H. Eugene, Chao, Yu-Sheng, Yeh, Teng-Kuang, and Jiaang, Weir-Torn
- Subjects
- *
LEUKEMIA treatment , *MYELOID leukemia , *DRUG resistance , *BIOAVAILABILITY , *THIAZOLES , *POINT mutation (Biology) , *PYRAZOLES , *THERAPEUTICS - Abstract
Numerous FLT3 inhibitors have been explored as a viable therapy for the treatment of acute myeloid leukemia (AML). However, clinical data have been underwhelming due to incomplete inhibition of FLT3 or the emergence of resistant mutations treated with these older agents. We previously developed a series of 3-phenyl-1 H -5-pyrazolylamine derivatives as highly potent and selective FLT3 inhibitors with good in vivo efficacy using an intravenous (IV) route. However, the poor bioavailability of these pyrazole compounds limits the development of these promising antileukemic compounds for clinical use. Herein, we describe a novel class of 5-phenyl-thiazol-2-ylamine compounds that are multi-targeted FLT3 inhibitors. From this class of compounds, compound 7h was very potent against AML cell lines and exhibited excellent oral efficacy in AML xenograft models. In addition, further studies demonstrated that compound 7h exhibited potent in vitro and in vivo activities against clinically relevant AC220 ( 3 )-resistant kinase domain mutants of FLT3-ITD. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
7. Paclitaxel-loaded poly(γ-glutamic acid)-poly(lactide) nanoparticles as a targeted drug delivery system for the treatment of liver cancer
- Author
-
Liang, Hsiang-Fa, Chen, Chiung-Tong, Chen, Sung-Ching, Kulkarni, Anandrao R., Chiu, Ya-Ling, Chen, Mei-Chin, and Sung, Hsing-Wen
- Subjects
- *
CANCER treatment , *LIVER cancer , *DRUG delivery systems , *PHARMACEUTICAL technology - Abstract
Abstract: The study was to develop paclitaxel-loaded formulations using a novel type of self-assembled nanoparticles (P/NPs) composed of block copolymers synthesized by poly(γ-glutamic acid) and poly(lactide). For the potential of targeting liver cancer cells, galactosamine was conjugated on the prepared nanoparticles (Gal-P/NPs). In the in vitro studies, it was found that both the P/NPs and the Gal-P/NPs had a similar release profile of paclitaxel. The activity in inhibiting the growth of HepG2 cells by the Gal-P/NPs was comparable to that of a clinically available paclitaxel formulation (Phyxol®), while the P/NPs displayed a significantly less activity (). The biodistribution and anti-tumor efficacy of the prepared nanoparticles were studied in hepatoma-tumor-bearing nude mice. It was found that the groups injected with Phyxol®, the P/NPs or the Gal-P/NPs significantly delayed the tumor growth as compared to the control group injected with PBS (). Among all studied groups, the group injected with the Gal-P/NPs appeared to have the most significant efficacy in the reduction of the size of the tumor. This is because a large number of the Gal-P/NPs were observed at the tumor site, and subsequently released their encapsulated paclitaxel to inhibit the growth of the tumor. The aforementioned results indicated that the Gal-P/NPs prepared in the study had a specific interaction with the hepatoma tumor induced in nude mice via ligand-receptor recognition. Therefore, the prepared Gal-P/NPs may be used as a potential drug delivery system for the targeted delivery to liver cancers. [Copyright &y& Elsevier]
- Published
- 2006
- Full Text
- View/download PDF
8. Effects of boschnaloside from Boschniakia rossica on dysglycemia and islet dysfunction in severely diabetic mice through modulating the action of glucagon-like peptide-1.
- Author
-
Lin, Lie-Chwen, Lee, Lin-Chien, Huang, Cheng, Chen, Chiung-Tong, Song, Jen-Shin, Shiao, Young-Ji, and Liu, Hui-Kang
- Abstract
Background: Boschniakia rossica is a well-known traditional Chinese medicine for tonifying kidney and improving impotence. Boschnaloside is the major iridoid glycoside in this herb but therapeutic benefits for diabetes remained to be evaluated.Hypothesis/purpose: The current investigation aims to study the antidiabetic effect and the underlying pharmacological mechanisms.Study Design and Methods: Receptor binding, cAMP production, Ins secretion, glucagon-like peptide 1 (GLP-1) secretion, and dipeptidyl peptidase-4 activity assays were performed. Therapeutic benefits of orally administrated boschnaloside (150 and 300 mg/kg/day) were evaluated using severely 12-week old female diabetic db/db mice (Hemoglobin A1c >10%).Results: Oral treatment of boschnaloside for 4 weeks improved diabetic symptoms including fasting blood sugar, hemoglobin A1c, glucose intolerance, and Homeostatic Model Assessment of Ins Resistance, accompanied by circulating GLP-1active and adiponectin levels. In addition, bochnaloside treatment improved islet/β cell function associated with an alteration of the pancreatic and duodenal homeobox 1 level. It was shown that boschnaloside interacted with the extracellular domain of GLP-1 receptor and enhanced glucose stimulated Ins secretion. Boschnaloside also augmented the insulinotropic effect of GLP-1. Finally, the presence of boschnaloside caused a reduction of dipeptidyl peptidase-4 activity while enhanced GLP-1 secretion from STC-1 cells.Conclusion: It appears that bochnaloside at oral dosage greater than 150 mg/kg/day exerts antidiabetic effects in vivo through modulating the action of GLP-1. [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
9. Multifunctional nanoparticles for oral protein drug delivery.
- Author
-
Chuang, Er-Yuan, Lin, Kun-Ju, Su, Fang-Yi, Mi, Fwu-Long, Chen, Chiung-Tong, Juang, Jyuhn-Huarng, and Sung, Hsing-Wen
- Subjects
PROTEIN drugs ,DRUG delivery systems ,NANOMEDICINE ,ORAL drug administration ,NANOTECHNOLOGY ,MEDICAL research - Published
- 2016
- Full Text
- View/download PDF
10. Identification of an oxime-containing C-glucosylarene as a potential inhibitor of sodium-dependent glucose co-transporter 2.
- Author
-
Yuan, Mao-Chia, Yeh, Teng-Kuang, Chen, Chiung-Tong, Song, Jen-Shin, Huang, Yu-Chen, Hsieh, Tsung-Chih, Huang, Chung-Yu, Huang, Yu-Ling, Wang, Min-Hsien, Wu, Szu-Huei, Yao, Chun-Hsu, Chao, Yu-Sheng, and Lee, Jinq-Chyi
- Subjects
- *
OXIMES , *GLUCOSE transporters , *HYPERGLYCEMIA , *GLYCOSIDES - Abstract
Treatment of hyperglycemia with drugs that block renal glucose reabsorption via inhibition of sodium-dependent glucose cotransporter 2 (SGLT2) is a novel approach to diabetes management. In this study, twenty-seven aryl C -glycosides bearing a C=N/C−N linkage at the glucosyl C6 position were designed, synthesized and evaluated for their inhibitory activity against human SGLT2 (hSGLT2). Compounds with good hSGLT2 inhibition were further investigated to determine their selectivity over hSGLT1. Of these, five representative aryl C -glycosides were chosen for pharmacokinetic analysis. Oxime 2a was determined to have the most promising pharmacokinetic properties and was selected for in vivo glucosuria and plasma glucose level studies, which found it to exhibit comparable efficacy to dapagliflozin ( 1 ). Furthermore, 2a was not found to exhibit either significant cytotoxicity (CC 50 > 50 μM) or human ether-a-go-go related gene (hERG) inhibition (2% inhibition at 10 μM). Taken together, these efforts culminated in the discovery of oxime 2a as a potential SGLT2 inhibitor. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
11. Peritoneal effluent MicroRNA profile for detection of encapsulating peritoneal sclerosis.
- Author
-
Wu, Kun-Lin, Chou, Che-Yi, Chang, Hui-Yin, Wu, Chih-Hsun, Li, An-Lun, Chen, Chien-Lung, Tsai, Jen-Chieh, Chen, Yi-Fan, Chen, Chiung-Tong, Tseng, Chin-Chung, Chen, Jin-Bor, Wang, I-Kuan, Hsu, Yu-Juei, Lin, Shih-Hua, Huang, Chiu-Ching, and Ma, Nianhan
- Subjects
- *
RECEIVER operating characteristic curves , *MICRORNA , *POLYMERASE chain reaction , *PERITONEAL dialysis - Abstract
• Long-term exposure of peritoneal dialysate and chronic inflammation were risk factors of encapsulating peritoneal sclerosis. • The miRNA-based model could be useful to assist to determine the possibility of encapsulating peritoneal sclerosis. • 5 miRNAs were key regulators of TGF-β signal pathway in mesothelial-mesenchymal transition and immune systems. • The interaction network of miRNAs and compounds indicated these these miRNAs have the therapeutic potential targets. Encapsulating peritoneal sclerosis (EPS) is a catastrophic complication of peritoneal dialysis (PD) with high mortality. Our aim is to develop a novel noninvasive microRNA (miRNA) test for EPS. We collected 142 PD effluents (EPS: 62 and non-EPS:80). MiRNA profiles of PD effluents were examined by a high-throughput real-time polymerase chain reaction (PCR) array to first screen. Candidate miRNAs were verified by single real-time PCR. The model for EPS prediction was evaluated by multiple logistic regression and machine learning. Seven candidate miRNAs were identified from the screening of PCR-array of 377 miRNAs. The top five area under the curve (AUC) values with 5 miRNA-ratios were selected using 127 samples (EPS: 56 vs non-EPS: 71) to produce a receiver operating characteristic curve. After considering clinical characteristics and 5 miRNA-ratios, the accuracies of the machine learning model of Random Forest and multiple logistic regression were boosted to AUC 0.97 and 0.99, respectively. Furthermore, the pathway analysis of miRNA associated targeting genes and miRNA-compound interaction network revealed that these five miRNAs played the roles in TGF-β signaling pathway. The model-based miRNA expressions in PD effluents may help determine the probability of EPS and provide further therapeutic opinion for EPS. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
12. Elucidating the signaling mechanism of an epithelial tight-junction opening induced by chitosan
- Author
-
Hsu, Li-Wen, Lee, Pei-Ling, Chen, Chiung-Tong, Mi, Fwu-Long, Juang, Jyuhn-Huarng, Hwang, Shiaw-Min, Ho, Yi-Cheng, and Sung, Hsing-Wen
- Subjects
- *
EPITHELIAL cells , *TIGHT junctions , *CHITOSAN , *MACROMOLECULES , *BIOAVAILABILITY , *CELLULAR signal transduction - Abstract
Abstract: Chitosan (CS) and its derivatives have been investigated as paracellular permeation enhancers for facilitating the oral bioavailability of hydrophilic macromolecules. As is well known, CS can transiently open the tight junctions (TJs) between epithelial cells, thus enhancing the paracellular permeability. However, the signaling mechanism that is related to the effect of CS on TJs remains unclear. Therefore, this study elucidates the potential transduction cascade of TJ opening in Caco-2 cell monolayers subsequent to CS exposure. Experimental results indicate that activation of integrin receptors on cell membranes significantly contributes to CS-mediated TJ disruption, initiating the cascade of TJ opening. Additionally, treatment of Caco-2 cell monolayers with CS leads to the clustering of integrins along the cell border, phosphorylation of FAK and Src tyrosine kinases, and results in the regulation of TJ permeability via the redistribution of TJ protein CLDN4 from the cell membrane to the cytosol. Elucidating the signaling mechanism of CS-induced TJ opening in intestinal cells significantly contributes to efforts to use CS and its derivatives as paracellular permeation enhancers. [Copyright &y& Elsevier]
- Published
- 2012
- Full Text
- View/download PDF
13. Synthesis and biological evaluation of novel C-indolylxylosides as sodium-dependent glucose co-transporter 2 inhibitors
- Author
-
Yao, Chun-Hsu, Song, Jen-Shin, Chen, Chiung-Tong, Yeh, Teng-Kuang, Hsieh, Tsung-Chih, Wu, Szu-Huei, Huang, Chung-Yu, Huang, Yu-Lin, Wang, Min-Hsien, Liu, Yu-Wei, Tsai, Chi-Hui, Kumar, Chidambaram Ramesh, and Lee, Jinq-Chyi
- Subjects
- *
ENZYME inhibitors , *STREPTOZOTOCIN , *CYCLOPROPYL compounds , *PHARMACOKINETICS , *STRUCTURE-activity relationships , *BLOOD sugar - Abstract
Abstract: Sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors are the current focus on the indication for the management of hyperglycemia in diabetes. Here, a novel series of C-linked indolylxyloside-based inhibitors of SGLT2 has been discovered. Structure–activity relationship studies revealed that substituents at the 7-position of the indole moiety and a p-cyclopropylphenyl group in the distal position were necessary for optimum inhibitory activity. The pharmacokinetic study demonstrates that the most potent compound 1i is metabolically stable with a low clearance in rats. In further efficacy study, 1i is found to significantly lower blood glucose levels of streptozotocin (STZ)-induced diabetic rats. [Copyright &y& Elsevier]
- Published
- 2012
- Full Text
- View/download PDF
14. Rational design and synthesis of potent and long-lasting glutamic acid-based dipeptidyl peptidase IV inhibitors
- Author
-
Tsai, Ting-Yueh, Hsu, Tsu, Chen, Chiung-Tong, Cheng, Jai-Hong, Chiou, Mei-Chun, Huang, Chih-Hsiang, Tseng, Ya-Ju, Yeh, Teng-Kuang, Huang, Chung-Yu, Yeh, Kai-Chia, Huang, Yu-Wen, Wu, Ssu-Hui, Wang, Min-Hsien, Chen, Xin, Chao, Yu-Sheng, and Jiaang, Weir-Torn
- Subjects
- *
DRUG design , *ORGANIC synthesis , *GLUTAMIC acid , *CD26 antigen , *ENZYME inhibitors , *PYRROLIDINE , *STRUCTURE-activity relationship in pharmacology , *THERAPEUTICS - Abstract
Abstract: A series of (2S)-cyanopyrrolidines with glutamic acid derivatives at the P2 site have been prepared and evaluated as inhibitors of dipeptidyl peptidase IV (DPP-IV). The structure–activity relationships (SAR) led to the discovery of potent 3-substituted glutamic acid analogues, providing enhanced chemical stability and excellent selectivity over the closely related enzymes, DPP8, DPP-II and FAP. Compound 13f exhibited the ability to both significantly decrease the glucose excursion and inhibit plasma DPP-IV activity. [Copyright &y& Elsevier]
- Published
- 2009
- Full Text
- View/download PDF
15. Novel trans-2-aryl-cyclopropylamine analogues as potent and selective dipeptidyl peptidase IV inhibitors
- Author
-
Tsai, Ting-Yueh, Hsu, Tsu, Chen, Chiung-Tong, Cheng, Jai-Hong, Yeh, Teng-Kuang, Chen, Xin, Huang, Chung-Yu, Chang, Chung-Nien, Yeh, Kai-Chia, Hsieh, Su-Huei, Chien, Chia-Hui, Chang, Yi-Wei, Huang, Chih-Hsiang, Huang, Yu-Wen, Huang, Chen-Lung, Wu, Ssu-Hui, Wang, Min-Hsien, Lu, Cheng-Tai, Chao, Yu-Sheng, and Jiaang, Weir-Torn
- Subjects
- *
PROPYLAMINE , *ORGANIC synthesis , *CD26 antigen , *CHEMICAL inhibitors , *STRUCTURE-activity relationships , *GLUCOSE tolerance tests , *LABORATORY mice - Abstract
Abstract: A series of trans-2-aryl-cyclopropylamine derived compounds were synthesized and evaluated their biological activities against DPP-IV. The structure-activity relationships (SAR) led to the discovery of novel series of DPP-IV inhibitors, having IC50 values of <100 nM with excellent selectivity over the closely related enzymes, DPP8, DPP-II and FAP. The studies identified a potent and selective DPP-IV inhibitor 24b, which exhibited the ability to both significantly inhibit plasma DPP-IV activity in rats and improve glucose tolerance in lean mice and diet induced obese mice. [Copyright &y& Elsevier]
- Published
- 2009
- Full Text
- View/download PDF
16. Shengmai San reduces hepatic lipids and lipid peroxidation in rats fed on a high-cholesterol diet
- Author
-
Yao, Hsien-Tsung, Chang, Yi-Wei, Chen, Chiung-Tong, Chiang, Meng-Tsan, Chang, Ling, and Yeh, Teng-Kuang
- Subjects
- *
CHOLESTEROL , *ISOPENTENOIDS , *THERAPEUTICS , *HEART diseases , *PEROXIDATION - Abstract
Abstract: Shengmai San (SMS), which is comprised of the medicinal herbs of Panax ginseng C.A. Meyer, Schisandra chinensis Baill., and Ophiopogon japonicus Ker-Gawl (2:1:2)., is a traditional Chinese medicine being used for treating coronary heart disease. The aim of this study was to investigate the effects of SMS on the plasma and liver lipids, lipid peroxidation and antioxidant systems in liver and heart of cholesterol-fed rats. Rats were fed on a high-cholesterol (0.5%) diet (control group), high-cholesterol diet containing 2% SMS (2% SMS group) and 4% SMS (4% SMS group) for four weeks. The oxidative stress marker (thiobarbituric acid reactive substances, TBARS) and antioxidant defense systems including glutathione (GSH), glutathione peroxidase (GSH-Px), glutathione-S-transferase (GST) and superoxide dismutase (SOD) activities in rat liver and heart were evaluated. Results showed that rats fed with SMS-containing diet had reduced the H2O2-induced erythrocytes susceptibility to hemolysis, and 4% SMS feeding rats had higher plasma GSH concentration compared to the animals fed with the control diet. However, SMS had no effect on plasma lipids (total cholesterol, triglyceride and high-density lipoprotein cholesterol) and TBARS concentration. On the other hand, rats fed with the 4% SMS diet reduced the hepatic cholesterol and triglyceride contents. Fecal bile acid excretion was significantly increased in rats fed with the SMS-containing diet. Higher hepatic GSH and lower TBARS concentrations were observed in rats fed with the 4% SMS diet compared with the rats fed with the control diet. No significant difference in activities of GSH-Px, GST and SOD was found in liver and heart after the SMS treatment. Results from this study indicate that the SMS may reduce hepatic lipids and lipid peroxidation in rats. [Copyright &y& Elsevier]
- Published
- 2008
- Full Text
- View/download PDF
17. 3-[2-((2S)-2-Cyano-pyrrolidin-1-yl)-2-oxo-ethylamino]-3-methyl-butyramide analogues as selective DPP-IV inhibitors for the treatment of type-II diabetes
- Author
-
Coumar, Mohane Selvaraj, Chang, Chung-Nien, Chen, Chiung-Tong, Chen, Xin, Chien, Chia-Hui, Tsai, Ting-Yueh, Cheng, Jai-Hong, Wu, Hsin-Yi, Han, Chia-Hung, Wu, Ssu-Hui, Huang, Yu-Wen, Hsu, Tsu, Hsu, Li-Jen, Chao, Yu-Sheng, Hsieh, Hsing-Pang, and Jiaang, Weir-Torn
- Subjects
- *
ENDOCRINE diseases , *CARBOHYDRATE intolerance , *BLOOD plasma , *AROMATIC amines - Abstract
Abstract: Based on the structures of NVP-DPP728 (1) and NVP-LAF237 (Vildagliptin, 2), three series of DPP-IV inhibitors were synthesized by linking substituted anilines, benzylamines, and phenylethylamines to (2S)-cyanopyrrolidine through a linker. More than 20 compounds were evaluated for their in vitro DPP-IV inhibition and selectivity profile over DPP-II, DPP8, and FAP enzymes. Selected compounds 5f and 7i showed in vivo plasma DPP-IV inhibition and inhibited glucose excursion in OGTT after oral administration in Wistar rats. Compound 5f (DPP-IV IC50 =116nM) has the potential for development as antidiabetic agent. [Copyright &y& Elsevier]
- Published
- 2007
- Full Text
- View/download PDF
18. Non-lethal Candida albicans cph1/cph1 efg1/efg1 mutant partially protects mice from systemic infections by lethal wild-type cells
- Author
-
Yang, Yun-Liang, Wang, Chih-Wei, Chen, Chiung-Tong, Wang, Min-Hsien, Hsiao, Chin-Fu, and Lo, Hsiu-Jung
- Subjects
- *
CANDIDA albicans , *MICROBIAL virulence -- Immunological aspects , *LETHAL mutations , *ANIMAL models in research , *LABORATORY mice , *FUNGI - Abstract
Abstract: Although Candida albicans cph1/cph1 efg1/efg1 mutant cells are not lethal to mice, they proliferated in infected mice instead of simply being cleared by the host immune system. Here, we have shown that the cph1/cph1 efg1/efg1 mutant partially protects mice from systemic infections by the lethal wild-type Candida albicans cells. Our results further indicate that a second dose of the cph1/cph1 efg1/efg1 mutant did not boost the degree of protection. [Copyright &y& Elsevier]
- Published
- 2009
- Full Text
- View/download PDF
19. Natural fucoidans inhibit coronaviruses by targeting viral spike protein and host cell furin.
- Author
-
Yang, Cheng-Wei, Hsu, Hsing-Yu, Lee, Yue-Zhi, Jan, Jia-Tsrong, Chang, Sui-Yuan, Lin, Yi-Ling, Yang, Ruey-Bing, Chao, Tai-Ling, Liang, Jian-Jong, Lin, Shu-Jing, Liao, Chun-Che, Chang, Chih-Shin, Sytwu, Huey-Kang, Hung, Ming-Shiu, Chen, Chiung-Tong, and Lee, Shiow-Ju
- Subjects
- *
VIRAL proteins , *HOST-virus relationships , *VIRUS diseases , *GENE expression profiling , *CORONAVIRUSES , *CELL receptors - Abstract
[Display omitted] • Fucoidan targets viral spike and host furin to block coronaviral entry. • Fucoidan inhibits viral entry and infection of HCoV-OC43 in vitro. • Fucoidan inhibits viral entry and infection of SARS-CoV-2 in vitro. • Fucoidan effectively inhibits infection by SARS-CoV-2 in vivo. Fucoidans are a class of long chain sulfated polysaccharides and have multiple biological functions. Herein, four natural fucoidans extracted from Fucus vesiculosus , F. serratus, Laminaria japonica and Undaria pinnatifida , were tested for their HCoV-OC43 inhibition and found to demonstrate EC 50 values ranging from 0.15 to 0.61 µg/mL. That from U. pinnatifida exhibited the most potent anti-HCoV-OC43 activity with an EC 50 value of 0.15 ± 0.02 µg/mL, a potency largely independent of its sulfate content. Comparison of the gene expression profiles of fucoidan-treated and untreated cells infected with HCoV-OC43 revealed that fucoidan treatment effectively diminished HCoV-OC43 gene expressions associated with induced chemokines, cytokines and viral activities. Further studies using a highly fucoidan-resistant HCoV-OC43 determined that fucoidan inhibited HCoV-OC43 infection via interfering with viral entry and led to the identification of the specific site on the N-terminal region of spike protein, that located adjacent to the host cell receptor binding domain, targeted by the virus. Furthermore, in a SARS-CoV-2 pseudovirus neutralization assay, fucoidan also blocked SARS-CoV-2 entry. In vitro and in vivo, fucoidan decreased SARS-CoV-2 viral loads and inhibited viral infection in Calu-3 or Vero E6 cells and SARS-CoV-2 infected hamsters, respectively. Fucoidan was also found to inhibit furin activity, and reported furin inhibitors were found to inhibit viral infection by wild type HCoV-OC43 or SARS-CoV-2. Accordingly, we conclude that fucoidans inhibit coronaviral infection by targeting viral spike protein and host cell furin to interfere with viral entry. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
20. A novel, potent, and orally bioavailable thiazole HCV NS5A inhibitor for the treatment of hepatitis C virus.
- Author
-
Yeh, Teng-Kuang, Kang, Iou-Jiun, Hsu, Tsu-An, Lee, Yen-Chun, Lee, Chung-Chi, Hsu, Sheng-Ju, Tian, Ya-Wen, Yang, Hui-Yun, Chen, Chiung-Tong, Chao, Yu-Sheng, Yueh, Andrew, and Chern, Jyh-Haur
- Subjects
- *
THIAZOLES , *HEPATITIS C treatment , *AMIDE derivatives , *SMALL molecules , *DIASTEREOISOMERS , *CYCLOALKYL group , *PHARMACOKINETICS - Abstract
Abstract A medicinal chemistry program based on the small-molecule HCV NS5A inhibitor daclatasvir has led to the discovery of dimeric phenylthiazole compound 8 , a novel and potent HCV NS5A inhibitor. The subsequent SAR studies and optimization revealed that the cycloalkyl amide derivatives 27a - 29a exhibited superior potency against GT1b with GT1b EC 50 values at picomolar concentration. Interestingly, high diastereospecificity for HCV inhibition was observed in this class with the (1 R ,2 S ,1′ R ,2′ S) diastereomer displaying the highest GT1b inhibitory activity. The best inhibitor 27a was found to be 3-fold more potent (GT1b EC 50 = 0.003 nM) than daclatasvir (GT1b EC 50 = 0.009 nM) against GT1b, and no detectable in vitro cytotoxicity was observed (CC 50 > 50 μM). Pharmacokinetic studies demonstrated that compound 27a had an excellent pharmacokinetic profiles with a superior oral exposure and desired bioavailability after oral administration in both rats and dogs, and therefore it was selected as a developmental candidate for the treatment of HCV infection. Graphical abstract Image 1 Highlights • A novel class of dimeric phenylthiazole derivatives was identified as potent HCV NS5A inhibitors. • Several inhibitors showed GT1b potency at picomolar concentrations. • Compound 27a showed superior GT1b potency and promising pharmacokinetic properties in both rats and dogs. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
21. The in vivo antinociceptive and μ-opioid receptor activating effects of the combination of N-phenyl-2′,4′-dimethyl-4,5′-bi-1,3-thiazol-2-amines and naloxone.
- Author
-
Lin, Shu-Yu, Kuo, Yu-Hsien, Tien, Ya-Wen, Ke, Yi-Yu, Chang, Wan-Ting, Chang, Hsiao-Fu, Ou, Li-Chin, Law, Ping-Yee, Xi, Jing-Hua, Tao, Pao-Luh, Loh, Horace H., Chao, Yu-Sheng, Shih, Chuan, Chen, Chiung-Tong, Yeh, Shiu-Hwa, and Ueng, Shau-Hua
- Subjects
- *
ANALGESICS , *OPIOID receptors , *PHENYL compounds , *THIAZOLE derivatives , *NALOXONE - Abstract
Abstract Morphine is widely used for the treatment of severe pain. This analgesic effect is mediated principally by the activation of μ-opioid receptors (MOR). However, prolonged activation of MOR also results in tolerance, dependence, addiction, constipation, nausea, sedation, and respiratory depression. To address this problem, we sought alternative ways to activate MOR – either by use of novel ligands, or via a novel activation mechanism. To this end, a series of compounds were screened using a sensitive CHO-K1/MOR/Gα15 cell-based FLIPR® calcium high-throughput screening (HTS) assay, and the bithiazole compound 5a was identified as being able activate MOR in combination with naloxone. Structural modifications of 5a resulted in the discovery of lead compound 5j , which could effectively activate MOR in combination with the MOR antagonist naloxone or naltrexone. I n vivo , naloxone in combination with 100 mg/kg of compound 5j elicited antinociception in a mouse tail-flick model with an ED 50 of 17.5 ± 4 mg/kg. These results strongly suggest that the mechanism by which the 5j /naloxone combination activates MOR is worthy of further study, as its discovery has the potential to yield an entirely novel class of analgesics. Graphical abstract Image 1 Highlights • A HTS assay identified 5a as being able to activate MOR in combination with naloxone. • Compound 5j /naloxone demonstrated anti-nociceptive effect in B6 mice. • This finding has the potential to open up a new area in pain treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
22. Strategies for improving diabetic therapy via alternative administration routes that involve stimuli-responsive insulin-delivering systems.
- Author
-
Lin, Yu-Jung, Mi, Fwu-Long, Lin, Po-Yen, Miao, Yang-Bao, Huang, Tringyo, Chen, Kuan-Hung, Chen, Chiung-Tong, Chang, Yen, and Sung, Hsing-Wen
- Subjects
- *
DRUG administration , *ALTERNATIVE medicine , *SUBCUTANEOUS injections , *INSULIN - Abstract
The encapsulation of insulin in micro- or nanodelivery systems may eliminate the need for frequent subcutaneous injections, improving the quality of life of diabetic patients. Formulations for oral, intranasal, pulmonary, subcutaneous, and transdermal administration have been developed. The use of stimuli-responsive polymeric carriers that can release the encapsulated drug in response to changes of the environmental stimuli or external activation enables the design of less invasive or non-invasive systems for smart insulin delivery from depots in the body. This article will look at strategies for the development of responsive delivery systems and the future meeting of the demands of new modes of insulin delivery. Unlabelled Image [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
23. Enhanced B-Raf-mediated NRF2 gene transcription and HATs-mediated NRF2 protein acetylation contributes to ABCC1-mediated chemoresistance and glutathione-mediated survival in acquired topoisomerase II poison-resistant cancer cells.
- Author
-
Chen, Huang-Hui, Chang, Hsin-Huei, Chang, Jang-Yang, Tang, Ya-Chu, Cheng, Yung-Chi, Lin, Li-Mei, Cheng, Shu-Ying, Huang, Chih-Hsiang, Sun, Man-Wu, Chen, Chiung-Tong, and Kuo, Ching-Chuan
- Subjects
- *
DNA topoisomerase II , *CANCER cells , *ANTIOXIDANTS , *RNA interference , *ATP-binding cassette transporters - Abstract
Nuclear factor erythroid-2-related factor 2 (NRF2) mainly regulates transcriptional activation through antioxidant-responsive elements (AREs) present in the promoters of NRF2 target genes. Recently, we found that NRF2 was overexpressed in a KB-derived drug-resistant cancer cell panel. In this panel, KB-7D cells, which show acquired resistance to topoisomerase II (Top II) poisons, exhibited the highest NRF2 activation. To investigate whether NRF2 directly contributed to acquired resistance against Top II poisons, we manipulated NRF2 by genetic and pharmacological approaches. The result demonstrated that silencing of NRF2 by RNA interference increased the sensitivity and treatment with NRF2 activator decreased the sensitivity of KB and KB-7D cells toward Top II poisons. Further, increased B-Raf – mediated NRF2 gene transcription and HATs – mediated NRF2 protein acetylation activated NRF2 signaling in KB-7D cells. Moreover, increased binding of NRF2 to an ARE in the promoter of ATP-binding cassette subfamily C member 1 ( ABCC1 ) directly contributed to Top II poison resistance. In addition, activation of NRF2 increased glutathione level and antioxidant capacity in KB-7D cells compared with that in KB cells; moreover, high glutathione level provided survival advantage to KB-7D cells. Our study is the first to show that aberrant NRF2 activation is via increased B-Raf–mediated NRF2 gene transcription and HATs–mediated NRF2 protein acetylation, which increases the acquired resistance and promote the survival of Top II poison-resistant cancer cells. Importantly, NRF2 downstream effectors ABCC1 and glutathione directly contribute to acquired resistance and survival, respectively. These results suggest that blockade of NRF2 signaling may enhance therapeutic efficacy and reduce the survival of Top II poison-refractory tumors in clinical. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
24. Benzo[b]thiophene-2-carboxamides as novel opioid receptor agonists with potent analgesic effect and reduced constipation.
- Author
-
Kuppusamy, Ramajayam, Hsu, Ying-Ting, Ke, Yi-Yu, Chang, Po-Wei, Chang, Yung-Chiao, Chang, Hsiao-Fu, Wang, Pei-Chen, Lin, Yu-Hao, Huang, Yu-Chen, Yeh, Teng-Kuang, Chuang, Jian-Ying, Loh, Horace H., Shih, Chuan, Chen, Chiung-Tong, Yeh, Shiu-Hwa, and Ueng, Shau-Hua
- Subjects
- *
OPIOID receptors , *OPIOID peptides , *CYCLIC adenylic acid , *PEPTIDE receptors , *CONSTIPATION , *RACEMIC mixtures - Abstract
Currently, there is a significant unmet need for novel analgesics with fewer side effects. In this study, we carried out structural modification of a hit compound previously identified in an artificial-intelligence (AI) virtual screening and discovered the potent analgesic, benzo[b]thiophene-2-carboxamide analog (compound 25) with new structural scaffold. We investigated the signaling pathways of opioid receptors mediated by compound 25 , and found this racemic compound activated mu-opioid receptor through the cyclic adenosine monophosphate (cAMP) and β-arrestin-2-mediated pathways with strong potency and efficacy, and accompanying nociceptin-orphanin FQ opioid peptide and delta-opioid receptors through the cAMP pathway with weak potencies. Compound 25 elicited potent antinociception in thermal-stimulated pain (ED 50 value of 127.1 ± 34.65 μg/kg) and inflammatory-induced allodynia models with less gastrointestinal transit inhibition and antinociceptive tolerance than morphine. Overall, this study revealed a novel analgesic with reduced risks of side effects. [Display omitted] • Benzo[b]thiophene-2-carboxamides were identified as potent opioid receptor agonists. • Compound 25 demonstrates potent antinociception in thermal nociceptive mouse model. • Compound 25 exerts less potent constipation than antinociception. • Compound 25 demonstrates less antinociceptive tolerance than morphine. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
25. N-Indolylglycosides bearing modifications at the glucose C6-position as sodium-dependent glucose co-transporter 2 inhibitors.
- Author
-
Chu, Kuang-Feng, Yao, Chun-Hsu, Song, Jen-Shin, Chen, Chiung-Tong, Yeh, Teng-Kuang, Hsieh, Tsung-Chih, Huang, Chung-Yu, Wang, Min-Hsien, Wu, Szu-Huei, Chang, Wei-En, Chao, Yu-Sheng, and Lee, Jinq-Chyi
- Subjects
- *
GLUCOSE transporters , *TYPE 2 diabetes treatment , *STRUCTURE-activity relationship in pharmacology , *AMIDE derivatives , *PHARMACOKINETICS - Abstract
Suppression of glucose reabsorption through the inhibition of sodium-dependent glucose co-transporter 2 (SGLT2) is a promising therapeutic approach for the treatment of type 2 diabetes. To investigate the effect of C6-substitution on inhibition of SGLT2 by N -indolylglucosides, a small library of 6-triazole, 6-amide, 6-urea, and 6-thiourea N -indolylglycosides were synthesized and tested. A detailed structure–activity relationship (SAR) study culminated in the identification of 6-amide derivatives 6a and 6o as potent SGLT2 inhibitors, which were further tested for inhibitory activity against SGLT1. The data obtained indicated that 6a and 6o are mildly to moderately selective for SGLT2 over SGLT1. Both compounds were also evaluated in a urinary glucose excretion test and pharmacokinetic study; 6a was found capable of inducing urinary glucose excretion in normal SD rats. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
26. Self-assembling bubble carriers for oral protein delivery.
- Author
-
Chuang, Er-Yuan, Lin, Kun-Ju, Lin, Po-Yen, Chen, Hsin-Lung, Wey, Shiaw-Pyng, Mi, Fwu-Long, Hsiao, Hsu-Chan, Chen, Chiung-Tong, and Sung, Hsing-Wen
- Subjects
- *
PROTEIN drugs , *ORAL medication , *MOLECULAR self-assembly , *INSULIN , *HYPOGLYCEMIC agents , *SURFACE active agents - Abstract
Successful oral delivery of therapeutic proteins such as insulin can greatly improve the quality of life of patients. This study develops a bubble carrier system by loading diethylene triamine pentaacetic acid (DTPA) dianhydride, a foaming agent (sodium bicarbonate; SBC), a surfactant (sodium dodecyl sulfate; SDS), and a protein drug (insulin) in an enteric-coated gelatin capsule. Following oral administration to diabetic rats, the intestinal fluid that has passed through the gelatin capsule saturates the mixture; concomitantly, DTPA dianhydride produces an acidic environment, while SBC decomposes to form CO 2 bubbles at acidic pH. The gas bubbles grow among the surfactant molecules (SDS) owing to the expansion of the generated CO 2 . The walls of the CO 2 bubbles consist of a self-assembled film of water that is in nanoscale and may serve as a colloidal carrier to transport insulin and DTPA. The grown gas bubbles continue to expand until they bump into the wall and burst, releasing their transported insulin, DTPA, and SDS into the mucosal layer. The released DTPA and SDS function as protease inhibitors to protect the insulin molecules as well as absorption enhancers to augment their epithelial permeability and eventual absorption into systemic circulation, exerting their hypoglycemic effects. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
27. Treatment of chemotherapy-induced neutropenia in a rat model by using multiple daily doses of oral administration of G-CSF-containing nanoparticles.
- Author
-
Su, Fang-Yi, Chuang, Er-Yuan, Lin, Po-Yen, Chou, Yi-Chun, Chen, Chiung-Tong, Mi, Fwu-Long, Wey, Shiaw-Pyng, Yen, Tzu-Chen, Lin, Kun-Ju, and Sung, Hsing-Wen
- Subjects
- *
DRUG therapy , *NEUTROPENIA , *LABORATORY rats , *ORAL drug administration , *GRANULOCYTE-colony stimulating factor , *NANOMEDICINE , *THERAPEUTICS - Abstract
Abstract: Chemotherapy-induced neutropenia often increases the likelihood of life-threatening infections. In this study, a nanoparticle (NP) system composed of chitosan and poly(γ-glutamic acid) conjugated with diethylene triamine pentaacetic acid (γPGA-DTPA) was prepared for oral delivery of granulocyte colony-stimulating factor (G-CSF), a hematopoietic growth factor. The therapeutic potential of this NP system for daily administration of G-CSF to treat neutropenia associated with chemotherapy was evaluated in a rat model. In vitro results indicate that the procedures of NP loading and release preserved the structural integrity and bioactivity of the G-CSF molecules adequately. Those results further demonstrated the enzymatic inhibition activity of γPGA-DTPA towards G-CSF against intestinal proteases. Additionally, the in vivo biodistribution study clearly identified accumulations of G-CSF in the heart, liver, bone marrow, and urinary bladder, an indication of systemic absorption of G-CSF; its relative bioavailability was approximately 13.6%. Moreover, significant glucose uptake was observed in bone marrow during G-CSF treatment, suggesting increased bone marrow metabolism and neutrophil production. Consequently, neutrophil count in the blood increased in a sustained manner; this fact may help a patient's immune system recover from the side effects of chemotherapy. [Copyright &y& Elsevier]
- Published
- 2014
- Full Text
- View/download PDF
28. Combination therapy via oral co-administration of insulin- and exendin-4-loaded nanoparticles to treat type 2 diabetic rats undergoing OGTT.
- Author
-
Chuang, Er-Yuan, Nguyen, Giang Thi Ha, Su, Fang-Yi, Lin, Kun-Ju, Chen, Chiung-Tong, Mi, Fwu-Long, Yen, Tzu-Chen, Juang, Jyuhn-Huarng, and Sung, Hsing-Wen
- Subjects
- *
COMBINATION drug therapy , *ORAL drug administration , *INSULIN therapy , *TYPE 2 diabetes treatment , *LABORATORY rats , *GLUCOSE tolerance tests - Abstract
Abstract: Current insulin therapy via subcutaneous administration can lead to occasional hypoglycemia and peripheral hyperinsulinemia, due to its nonphysiological route. This study evaluates the feasibility of using bovine insulin and exendin-4 in a form of combination therapy, as orally delivered by nanoparticles composed of chitosan and poly(γ-glutamic acid) (CS/γPGA NPs), to control blood glucose levels in rats with type 2 diabetes mellitus (T2DM) undergoing the oral glucose tolerance test. Experimental results indicate that CS/γPGA NPs could enhance the intestinal paracellular permeation; consequently, the exogenous bovine insulin and exendin-4 could be delivered into the liver and pancreas, where they could elicit their glucoregulatory activities. In response to the stimulus of exogenously delivered bovine insulin and the endogenously secreted rat insulin stimulated by the ingested exendin-4, significant glucose utilizations were found in the cardiac and skeletal muscles, resulting in the glucose-lowering effect. Owing to its synergic stimulation effects, the hypoglycemic effect of oral ingestion of NPs containing bovine insulin and exendin-4 was significantly greater than that of the group solely treated with insulin NPs. Above results demonstrate that oral combination therapy with bovine insulin and exendin-4 improves the modulation of blood glucose levels in T2DM rats, making it highly promising for treating those T2DM patients not adequately controlled by the current insulin therapy. [Copyright &y& Elsevier]
- Published
- 2013
- Full Text
- View/download PDF
29. Discovery of 3-phenyl-1H-5-pyrazolylamine derivatives containing a urea pharmacophore as potent and efficacious inhibitors of FMS-like tyrosine kinase-3 (FLT3).
- Author
-
Lin, Wen-Hsing, Hsu, John T.-A., Hsieh, Shu-Yi, Chen, Chiung-Tong, Song, Jen-Shin, Yen, Shih-Chieh, Hsu, Tsu, Lu, Cheng-Tai, Chen, Chun-Hwa, Chou, Ling-Hui, Yang, Yung-Ning, Chiu, Ching-Hui, Chen, Ching-Ping, Tseng, Ya-Ju, Yen, Kuei-Jung, Yeh, Ching-Fang, Chao, Yu-Sheng, Yeh, Teng-Kuang, and Jiaang, Weir-Torn
- Subjects
- *
DRUG development , *PROTEIN-tyrosine kinase inhibitors , *AMINE derivatives , *AMINES , *UREA , *LIGANDS (Biochemistry) , *CLINICAL trials , *LEUKEMIA treatment , *MYELOID leukemia , *THERAPEUTICS - Abstract
Abstract: Preclinical investigations and early clinical trials suggest that FLT3 inhibitors are a viable therapy for acute myeloid leukemia. However, early clinical data have been underwhelming due to incomplete inhibition of FLT3. We have developed 3-phenyl-1H-5-pyrazolylamine as an efficient template for kinase inhibitors. Structure–activity relationships led to the discovery of sulfonamide, carbamate and urea series of FLT3 inhibitors. Previous studies showed that the sulfonamide 4 and carbamate 5 series were potent and selective FLT3 inhibitors with good in vivo efficacy. Herein, we describe the urea series, which we found to be potent inhibitors of FLT3 and VEGFR2. Some inhibited growth of FLT3-mutated MOLM-13 cells more strongly than the FLT3 inhibitors sorafenib (2) and ABT-869 (3). In preliminary in vivo toxicity studies of the four most active compounds, 10f was found to be the least toxic. A further in vivo efficacy study demonstrated that 10f achieved complete tumor regression in a higher proportion of MOLM-13 xenograft mice than 4 and 5 (70% vs 10% and 40%). These results show that compound 10f possesses improved pharmacologic and selectivity profiles and could be more effective than previously disclosed FLT3 inhibitors in the treatment of acute myeloid leukemia. [Copyright &y& Elsevier]
- Published
- 2013
- Full Text
- View/download PDF
30. Effects of pH on molecular mechanisms of chitosan–integrin interactions and resulting tight-junction disruptions
- Author
-
Hsu, Li-Wen, Ho, Yi-Cheng, Chuang, Er-Yuan, Chen, Chiung-Tong, Juang, Jyuhn-Huarng, Su, Fang-Yi, Hwang, Shiaw-Min, and Sung, Hsing-Wen
- Subjects
- *
PH effect , *CHITOSAN , *INTEGRINS , *TIGHT junctions , *DRUG delivery systems , *PERMEABILITY , *F-actin - Abstract
Abstract: Chitosan (CS) is a potential paracellular permeation enhancer for trans-epithelial drug delivery; however, its ability to enhance epithelial permeability in a pH-dependent manner remains unclear. This study was designed to explore the underlying molecular mechanisms with regard to the effect of CS on tight junction (TJ) disruption at different pH environments in Caco-2 cell monolayers. The experimental results revealed that the direct interaction between CS and integrin αVβ3 on cell surfaces has a crucial role in CS-induced TJ opening, an indication of receptor activation. The mechanism of action appeared to be the electrostatic interaction between the positively-charged CS and the negatively-charged integrin αVβ3. This electrostatic interaction led to the conformation change of integrin αVβ3 and its clustering along the cell border, F-actin reorganization, and CLDN4 down-regulation, eventually resulting in the disruption of TJs and an increase in paracellular permeability. The above observations were all in a pH-dependent manner. As pH increased, CS became less positively charged, thereby losing its capability to interact with integrin αVβ3 and failing to induce the TJ opening. These consequences might help to better understand the molecular mechanism of TJ opening mediated by CS, thereby facilitating the use of CS for trans-epithelial drug delivery. [Copyright &y& Elsevier]
- Published
- 2013
- Full Text
- View/download PDF
31. 3-Phenyl-1H-5-pyrazolylamine-based derivatives as potent and efficacious inhibitors of FMS-like tyrosine kinase-3 (FLT3)
- Author
-
Hsu, John T.-A., Yeh, Teng-Kuang, Yen, Shih-Chieh, Chen, Chiung-Tong, Hsieh, Shu-Yi, Hsu, Tsu, Lu, Cheng-Tai, Chen, Chun-Hwa, Chou, Ling-Hui, Chiu, Ching-Hui, Chang, Yun-I, Tseng, Ya-Ju, Yen, Kuei-Rong, Chao, Yu-Sheng, Lin, Wen-Hsing, and Jiaang, Weir-Torn
- Subjects
- *
AMINE derivatives , *DRUG synergism , *PROTEIN-tyrosine kinase inhibitors , *STRUCTURE-activity relationship in pharmacology , *PHARMACEUTICAL research , *CARBAMATES , *CANCER cells , *LABORATORY mice - Abstract
Abstract: A new class of FLT3 inhibitors has been identified based on the 3-phenyl-1H-5-pyrazolylamine scaffold. The structure–activity relationships led to the discovery of two carbamate series, and some potent compounds within these two series exhibited better growth inhibition of FLT3-mutated MOLM-13 cells than FLT3 inhibitors sorafenib (2) and ABT-869 (3). In particular, compound 8d exhibited the ability to regress tumors in mouse xenograft model using MOLM-13 cells. [Copyright &y& Elsevier]
- Published
- 2012
- Full Text
- View/download PDF
32. Effects of chitosan-nanoparticle-mediated tight junction opening on the oral absorption of endotoxins
- Author
-
Sonaje, Kiran, Lin, Kun-Ju, Tseng, Michael T., Wey, Shiaw-Pyng, Su, Fang-Yi, Chuang, Er-Yuan, Hsu, Chia-Wei, Chen, Chiung-Tong, and Sung, Hsing-Wen
- Subjects
- *
CHITOSAN , *NANOPARTICLES , *ABSORPTION (Physiology) , *ENDOTOXINS , *HYDROGEN-ion concentration , *INSULIN , *HYPOGLYCEMIA , *TOMOGRAPHY , *TRANSMISSION electron microscopy - Abstract
Abstract: Recently, we reported a pH-responsive nanoparticle (NP) system shelled with chitosan (CS), which could effectively increase the oral absorption of insulin and produce a hypoglycemic effect, presumably due to the CS-mediated tight junction (TJ) opening. It has been often questioned whether CS can also enhance the absorption of endotoxins present in the small intestine. To address this concern, we studied the effect of CS NPs on the absorption of lipopolysaccharide (LPS), the most commonly found toxin in the gastrointestinal tract. To follow their biodistribution by the single-photon emission computed tomography/computed tomography, LPS and insulin were labeled with 99mTc-pertechnetate (99mTc-LPS) and 123iodine (123I-insulin), respectively. The 99mTc-LPS was ingested 1 h prior to the administration of the 123I-insulin-loaded NPs to mimic the physiological conditions. The confocal and TEM micrographs show that the orally administered CS NPs were able to adhere and infiltrate through the mucus layer, approach the epithelial cells and mediate to open their TJs. The radioactivity associated with LPS was mainly restricted to the gastrointestinal tract, whereas 123I-insulin started to appear in the urinary bladder at 3 h post administration. This observation indicates that the insulin-loaded in CS NPs can traverse across the intestinal epithelium and enter the systemic circulation, whereas LPS was unable to do so, probably because of the charge repulsion between the anionic LPS in the form of micelles and the negatively charged mucus layer. Our in vivo toxicity study further confirms that the enhancement of paracellular permeation by CS NPs did not promote the absorption of LPS. These results suggest that CS NPs can be used as a safe carrier for oral delivery of protein drugs. [Copyright &y& Elsevier]
- Published
- 2011
- Full Text
- View/download PDF
33. Discovery and evaluation of 3-phenyl-1H-5-pyrazolylamine-based derivatives as potent, selective and efficacious inhibitors of FMS-like tyrosine kinase-3 (FLT3)
- Author
-
Lin, Wen-Hsing, Hsieh, Shu-Yi, Yen, Shih-Chieh, Chen, Chiung-Tong, Yeh, Teng-Kuang, Hsu, Tsu, Lu, Cheng-Tai, Chen, Ching-Ping, Chen, Chun-Wha, Chou, Ling-Hui, Huang, Yu-Lin, Cheng, An-Huei, Chang, Yun-I, Tseng, Ya-Ju, Yen, Kuei-Rong, Chao, Yu-Sheng, Hsu, John T.-A., and Jiaang, Weir-Torn
- Subjects
- *
AMINES , *PROTEIN-tyrosine kinases , *CLINICAL trials , *LEUKEMIA treatment , *MYELOID leukemia , *TUMOR treatment , *LABORATORY mice , *XENOGRAFTS , *DRUG efficacy - Abstract
Abstract: Preclinical investigations and early clinical trial studies suggest that FLT3 inhibitors offer a viable therapy for acute myeloid leukemia. However, early clinical data for direct FLT3 inhibitors provided only modest results because of the failure to fully inhibit FLT3. We have designed and synthesized a novel class of 3-phenyl-1H-5-pyrazolylamine-derived compounds as FLT3 inhibitors which exhibit potent FLT3 inhibition and high selectivity toward different receptor tyrosine kinases. The structure–activity relationships led to the discovery of two series of FLT3 inhibitors, and some potent compounds within these two series exhibited comparable potency to FLT3 inhibitors sorafenib (3) and ABT-869 (4) in both wt-FLT3 enzyme inhibition and FLT3-ITD inhibition on cell growth (MOLM-13 and MV4;11 cells). In particular, the selected compound 12a exhibited the ability to regress tumors in mouse xenograft models using MOLM-13 and MV4;11 cells. [Copyright &y& Elsevier]
- Published
- 2011
- Full Text
- View/download PDF
34. (2S,4S)-1-[2-(1,1-Dimethyl-3-oxo-3-pyrrolidin-1-yl-propylamino)acetyl]-4-fluoro-pyrrolidine-2-carbonitrile: A potent, selective, and orally bioavailable dipeptide-derived inhibitor of dipeptidyl peptidase IV
- Author
-
Yeh, Teng-Kuang, Tsai, Ting-Yueh, Hsu, Tsu, Cheng, Jai-Hong, Chen, Xin, Song, Jen-Shin, Shy, Horng-Shing, Chiou, Mei-Chun, Chien, Chia-Hui, Tseng, Ya-Ju, Huang, Chung-Yu, Yeh, Kai-Chia, Huang, Yu-Lin, Huang, Chih-Hsiang, Huang, Yu-Wen, Wang, Min-Hsien, Tang, Hung-Kuan, Chao, Yu-Sheng, Chen, Chiung-Tong, and Jiaang, Weir-Torn
- Subjects
- *
PYRROLIDINE , *ENZYME inhibitors , *BIOAVAILABILITY , *CD26 antigen , *AMINES , *LABORATORY rats , *ORAL drug administration - Abstract
Abstract: A series of 2-[3-[2-[(2S)-2-cyano-1-pyrrolidinyl]-2-oxoethylamino]-3-methyl-1-oxobutyl]-based DPP-IV inhibitors with various monocyclic amines were synthesized. The structure–activity relationships (SAR) led to the discovery of potent DPP-IV inhibitors, having IC50 values of <100nM with excellent selectivity over the closely related enzymes, DPP-II, DPP8, DPP9 and FAP (IC50 >20μM). Of these compounds, the analogues 12a, 12h and 12i exhibited a long-lasting ex vivo DPP-IV inhibition in rats. [Copyright &y& Elsevier]
- Published
- 2010
- Full Text
- View/download PDF
35. Effect of taurine supplementation on cytochrome P450 2E1 and oxidative stress in the liver and kidneys of rats with streptozotocin-induced diabetes
- Author
-
Yao, Hsien-Tsung, Lin, PinPin, Chang, Yi-Wei, Chen, Chiung-Tong, Chiang, Meng-Tsan, Chang, Ling, Kuo, Yu-Chun, Tsai, Hui-Ti, and Yeh, Teng-Kuang
- Subjects
- *
DRUG efficacy , *TAURINE , *CYTOCHROME P-450 , *OXIDATIVE stress , *LIVER diseases , *KIDNEY diseases , *LABORATORY rats , *STREPTOZOTOCIN , *DIABETES , *DRUG toxicity - Abstract
Abstract: To investigate whether diabetes-induced alterations of CYP2E1 and oxidative stress can be modulated by dietary taurine supplementation, male Wistar rats were divided into non-diabetic, diabetic, and diabetic taurine-supplemented groups (administered at 2% in the drinking water). Increased levels of CYP2E1-catalyzed p-nitrophenol hydroxylation were found in liver and kidney microsomes of rats with STZ-induced diabetes compared to those of non-diabetic control rats. Immunoblot and RT-PCR analyses of CYP2E1 protein and mRNA levels in the liver and kidneys showed the same trend as with enzyme activities. Taurine supplementation significantly decreased the enzyme activity and expression (protein and mRNA) of CYP2E1 in diabetic rat kidneys. Plasma β-hydroxybutyrate concentration was significantly reduced in taurine-treated diabetic rats. The induction of heme oxygenase-1 mRNA was suppressed by taurine treatment in diabetic rat kidneys. An increase in reduced glutathione (GSH) and a higher ratio of reduced to oxidized glutathione (GSH/GSSG) together with lower values of thiobarbituric acid-reactive substances (TBARS) were observed in the kidneys of taurine-treated diabetic rats. However, taurine supplementation caused only a slight or insignificant effect on these alternations in the liver of diabetic rats. Our results show dietary taurine may reduce CYP2E1 expression and activity, and oxidative stress in kidneys of diabetic rats. [Copyright &y& Elsevier]
- Published
- 2009
- Full Text
- View/download PDF
36. In vivo evaluation of safety and efficacy of self-assembled nanoparticles for oral insulin delivery
- Author
-
Sonaje, Kiran, Lin, Yu-Hsin, Juang, Jyuhn-Huarng, Wey, Shiaw-Pyng, Chen, Chiung-Tong, and Sung, Hsing-Wen
- Subjects
- *
DRUG efficacy , *ORAL medicine , *HYDROGEN-ion concentration , *BIOMEDICAL materials ,DOSE-response relationship of insulin ,INSULIN pharmacokinetics - Abstract
Abstract: A variety of approaches have been studied in the past to overcome the problems encountered with the oral delivery of insulin, but with little success. In this study, self-assembled nanoparticles (NPs) with a pH-sensitive characteristic were prepared by mixing the anionic poly-γ-glutamic acid solution with the cationic chitosan solution in the presence of MgSO4 and sodium tripolyphosphate. The in vitro results found that the transport of insulin across Caco-2 cell monolayers by NPs appeared to be pH-dependent; with increasing pH, the amount of insulin transported decreased significantly. An in vivo toxicity study was performed to establish the safety of the prepared NPs after oral administration. Additionally, the impact of orally administered NPs on the pharmacodynamics (PD) and pharmacokinetics (PK) of insulin was evaluated in a diabetic rat model. The in vivo results indicated that the prepared NPs could effectively adhere on the mucosal surface and their constituted components were able to infiltrate into the mucosal cell membrane. The toxicity study indicated that the NPs were well tolerated even at a dose 18 times higher than that used in the PD/PK study. Oral administration of insulin-loaded NPs demonstrated a significant hypoglycemic action for at least 10h in diabetic rats and the corresponding relative bioavailability of insulin was found to be 15.1±0.9%. These findings suggest that the NPs prepared in the study are a promising vehicle for oral delivery of insulin. [Copyright &y& Elsevier]
- Published
- 2009
- Full Text
- View/download PDF
37. Design and synthesis of novel orally selective and type II pan-TRK inhibitors to overcome mutations by property-driven optimization.
- Author
-
Li, Mu-Chun, Lin, Wen-Hsing, Wang, Pei-Chen, Su, Yu-Chieh, Chen, Pei-Yi, Fan, Chu-Min, Chen, Ching-Ping, Huang, Chen-Lung, Chiu, Chun-Hsien, Chang, Ling, Chen, Chiung-Tong, Yeh, Teng-Kuang, and Hsieh, Hsing-Pang
- Subjects
- *
GENE fusion , *COLORECTAL cancer , *STRUCTURE-activity relationships , *QUINAZOLINE , *ADULTS - Abstract
Rare oncogenic NTRK gene fusions result in uncontrolled TRK signaling leading to various adult and pediatric solid tumors. Based on the architecture of our multi-targeted clinical candidate BPR1K871 (10), we designed and synthesized a series of quinazoline compounds as selective and orally bioavailable type II TRK inhibitors. Property-driven and lead optimization strategies informed by structure-activity relationship studies led to the identification of 39 , which showed higher (about 15-fold) selectivity for TRKA over AURA and AURB, as well as potent cellular activity (IC 50 = 56.4 nM) against the KM12 human colorectal cancer cell line. 39 also displayed good AUC and oral bioavailability (F = 27%), excellent in vivo efficacy (TGI = 64%) in a KM12 xenograft model, and broad-spectrum anti -TRK mutant potency (IC 50 = 3.74–151.4 nM), especially in the double-mutant TRKA enzymatic assays. 39 is therefore proposed for further development as a next-generation, selective, and orally-administered type II TRK inhibitor. [Display omitted] • A next-generation orally selective type II TRK inhibitor was discovered. • Twenty-nine quinazoline-based analogues were designed and synthesized. • Property-driven strategy guided lead-to-candidate optimization. • 39 is a potent TRK inhibitor against both wild-type and mutant TRKs. • 39 demonstrated antitumor effectiveness in KM-12 xenograft model. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
38. Anti-angiogenic action of 5,5-diphenyl-2-thiohydantoin-N10 (DPTH-N10)
- Author
-
Liu, Yuan, Wu, Jender, Ho, Pei-Yin, Chen, Li-Ching, Chen, Chiung-Tong, Liang, Yu-Chih, Cheng, Cheng-Kuo, and Lee, Wen-Sen
- Subjects
- *
PROTEIN kinases , *BLOOD plasma , *VASCULAR endothelial growth factors , *BLOOD vessels , *ANIMAL experimentation , *AORTA , *CELL culture , *CELL physiology , *COMPARATIVE studies , *ENDOTHELIUM , *HYDANTOIN , *RESEARCH methodology , *MEDICAL cooperation , *NEOVASCULARIZATION inhibitors , *PHENYTOIN , *RESEARCH , *WESTERN immunoblotting , *EVALUATION research , *PRECIPITIN tests , *IN vitro studies , *PHARMACODYNAMICS - Abstract
Abstract: Previously, we demonstrated that 5,5-diphenyl-2-thiohydantoin (DPTH) exerts an anti-proliferation effect on subcultured human umbilical vein endothelial cells (HUVEC). In the present study, we show that 2(naphthalen-2-ylmethylsulfanyl)-5,5-diphenyl-1,5-dihydro-imidazol-4-one (DPTH-N10), a derivative compound of DPTH, exerts a 5 times stronger inhibition of [3H]thymidine incorporation into HUVEC as compared with DPTH and at very low concentrations (0–20μM) inhibited DNA synthesis and decreased cell number in cultured HUVEC in a concentration- and time-dependent manner, but not in human fibroblasts. [3H]thymidine incorporation analysis demonstrated that treatment of HUVEC with DPTH-N10 arrested the cell at the G0/G1 phase of the cell cycle. Western blot analysis revealed that the protein level of p21 in HUVEC increased after DPTH-N10 treatment. In contrast, the protein levels of p27, p53, cyclins A, D1, D3 and E, cyclin-dependent kinase (CDK)2, and CDK4 in HUVEC were not changed significantly after DPTH-N10 treatment. Immunoprecipitation showed that the formation of the CDK2–p21 complex, but not the CDK2–p27, CDK4–p21, and CDK4–p27 complex, was increased in the DPTH-N10-treated HUVEC. Kinase assay further demonstrated that CDK2, but not CDK4, kinase activity was decreased in the DPTH-N10-treated HUVEC. Pretreatment of HUVEC with a p21, but not p27, antisense oligonucleotide reversed the DPTH-N10-induced inhibition of [3H]thymidine incorporation into HUVEC. Taken together, these data suggest that DPTH-N10 inhibits HUVEC proliferation by increasing the level of p21 protein, which in turn inhibits CDK2 kinase activity, and finally interrupts the cell cycle. Capillary-like tube formation, aortic ring culture, and chick embryo chorioallantoic membrane (CAM) assays further demonstrated the anti-angiogenic effect of DPTH-N10. [Copyright &y& Elsevier]
- Published
- 2008
- Full Text
- View/download PDF
39. The inhibitory effect of polyunsaturated fatty acids on human CYP enzymes
- Author
-
Yao, Hsien-Tsung, Chang, Yi-Wei, Lan, Shih-Jung, Chen, Chiung-Tong, Hsu, John T.A., and Yeh, Teng-Kuang
- Subjects
- *
UNSATURATED fatty acids , *DOCOSAHEXAENOIC acid , *HYDROXYLATION , *ENZYMES - Abstract
Abstract: The inhibitory effect of saturated fatty acids (SFAs): palmitic acid (PA), stearic acid (SA) and polyunsaturated fatty acids (PUFAs): linoleic acid (LA), linolenic acid (LN), arachidonic acid (AA), eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) on six human drug-metabolizing enzymes (CYP1A2, 2C9, 2C19, 2D6, 2E1 and 3A4) was studied. Supersomes from baculovirus-expressing single isoforms were used as the enzyme source. Phenacetin O-deethylation (CYP1A2), diclofenac 4-hydroxylation (CYP2C9), mephenytoin 4-hydroxylation (CYP2C19), dextromethorphan O-demethylation (CYP2D6), chlorzoxazone 6-hydroxylation (CYP2E1) and midazolam 1-hydroxylation (CYP3A4) were used as the probes. Results show that all the five examined PUFAs competitively inhibited CYP2C9- and CYP2C19-catalyzed metabolic reactions, with Ki values ranging from 1.7 to 4.7 μM and 2.3 to 7.4 μM, respectively. Among these, AA, EPA and DHA tended to have greater inhibitory potencies (lower IC50 and Ki values) than LA and LN. In addition, these five PUFAs also competitively inhibited the metabolic reactions catalyzed by CYP1A2, 2E1 and 3A4 to a lesser extent (Ki values>10 μM). On the other hand, palmitic and stearic acids, the saturated fatty acids, had no inhibitory effect on the activities of six human CYP isozymes at concentrations up to 200 μM. Incubation of PUFAs with CYP2C9 or CYP2C19 in the presence of NADPH resulted in the decrease of PUFA concentrations in the incubation mixtures. These results indicate that the PUFAs are potent inhibitors as well as the substrates of CYP2C9 and CYP2C19. [Copyright &y& Elsevier]
- Published
- 2006
- Full Text
- View/download PDF
40. Substituted pyrrolidine-2,4-dicarboxylic acid amides as potent dipeptidyl peptidase IV inhibitors
- Author
-
Tsai, Ting-Yueh, Coumar, Mohane Selvaraj, Hsu, Tsu, Hsieh, Hsing-Pang, Chien, Chia-Hui, Chen, Chiung-Tong, Chang, Chung-Nien, Lo, Yu-Kang, Wu, Ssu-Hui, Huang, Chung-Yu, Huang, Yu-Wen, Wang, Min-Hsien, Wu, Hsin-Yi, Lee, Hong-Jen, Chen, Xin, Chao, Yu-Sheng, and Jiaang, Weir-Torn
- Subjects
- *
CD26 antigen , *PYRROLIDINE , *PEPTIDASE , *AMIDES - Abstract
Abstract: A series of substituted pyrrolidine-2,4-dicarboxylic acid amides were synthesized as potential antidiabetic agents, and many of them showed good in vitro DPP-IV inhibition (IC50 =2–250nM) with selectivity over DPP-II, DPP8, and FAP enzymes. Selected compounds 8c and 11a showed in vivo plasma DPP-IV inhibition after oral administration in Wistar rats. [Copyright &y& Elsevier]
- Published
- 2006
- Full Text
- View/download PDF
41. DBPR108, a novel dipeptidyl peptidase-4 inhibitor with antihyperglycemic activity.
- Author
-
Yeh, Kai-Chia, Yeh, Teng-Kuang, Huang, Chung-Yu, Hu, Chih-Bo, Wang, Min-Hsien, Huang, Yu-Wen, Chou, Ling-Hui, Ho, Hsuan-Hui, Song, Jen-Shin, Hsu, Tsu, Jiaang, Weir-Torn, Chao, Yu-Sheng, and Chen, Chiung-Tong
- Subjects
- *
CD26 antigen , *SMALL molecules , *GLUCOSE tolerance tests , *RATS , *SODIUM-glucose cotransporters , *DIABETES - Abstract
Dipeptidyl peptidase 4 (DPP-4) is a valid molecular drug target from which its inhibitors have been developed as medicines for treating diabetes. The present study evaluated a new synthetic DPP-4-specific inhibitor of small molecule DBPR108 for pharmacology and pharmacokinetic profiles. DBPR108 of various doses was orally administered to rats, diabetic mice, and dogs and the systemic circulating DPP-4 activities in the animals were measured to demonstrate the pharmacological mechanisms of action via DPP-4 inhibition. Upon an oral administration of DBPR108, the serum active GLP-1 and insulin levels of the rats challenged with an oral glucose ingestion were measured. Oral glucose tolerance test in diet-induced obese mice was performed to examine if DBPR108 increases the glucose tolerability in animals. Orally administered DBPR108 inhibited the systemic plasma DPP-4 activities in rats, dogs and diabetic mice in a dose-dependent manner. DBPR108 caused elevated serum levels of active GLP-1 and insulin in the rats. DBPR108 dose-dependently increased the glucose tolerability in diet-induced obese (DIO) mice and, furthermore, DIO mice treated with DBPR108 (0.1 mg/kg) in combination with metformin (50 or 100 mg/kg) showed a prominently strong increase in the glucose tolerability. DBPR108 is a novel DPP-4-selective inhibitor of small molecule that demonstrated potent in vivo pharmacological effects and good safety profiles in animals. DBPR108 is now a drug candidate being further developed in the clinical studies as therapeutics for treating diabetes. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
42. Potent and orally active purine-based fetal hemoglobin inducers for treating β-thalassemia and sickle cell disease.
- Author
-
Lai, Zheng-Sheng, Yeh, Teng-Kuang, Chou, Yu-Chi, Hsu, Tsu, Lu, Cheng-Tai, Kung, Fang-Chun, Hsieh, Ming-Yen, Lin, Chun-Hung, Chen, Chiung-Tong, James Shen, Che-Kun, and Jiaang, Weir-Torn
- Subjects
- *
SICKLE cell anemia , *FETAL hemoglobin , *HISTONE deacetylase inhibitors , *SYMPTOMS , *ANEMIA treatment , *STRUCTURE-activity relationships - Abstract
Reactivation of fetal hemoglobin (HbF) expression by therapeutic agents has been suggested as an alternative treatment to modulate anemia and the related symptoms of severe β-thalassemia and sickle cell disease (SCD). Hydroxyurea (HU) is the first US FDA-approved HbF inducer for treating SCD. However, approximately 25% of the patients with SCD do not respond to HU. A previous study identified TN1 (1) as a small-molecule HbF inducer. However, this study found that the poor potency and oral bioavailability of compound 1 limits the development of this inducer for clinical use. To develop drug-like compounds, further structure-activity relationship studies on the purine-based structure of 1 were conducted. Herein, we report our discovery of a more potent inducer, compound 13a , that can efficiently induce γ-globin gene expression at non-cytotoxic concentrations. The molecular mechanism of 13a, for the regulation HbF expression, was also investigated. In addition, we demonstrated that oral administration of 13a can ameliorate anemia and the related symptoms in SCD mice. The results of this study suggest that 13a can be further developed as a novel agent for treating hemoglobinopathies, such as β-thalassemia and SCD. Image 1 • Compound 13a displays potent antianemic activity. • Compound 13a overcomes resistance to hydroxyurea in primary human erythroid cells. • Compound 13a is not a histone deacetylase inhibitor. • Oral 13a treatments yield dose-dependent relief of anemia symptoms in SCD mice. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
43. A bubble bursting-mediated oral drug delivery system that enables concurrent delivery of lipophilic and hydrophilic chemotherapeutics for treating pancreatic tumors in rats.
- Author
-
Chen, Kuan-Hung, Miao, Yang-Bao, Shang, Chun-Yu, Huang, Tring-Yo, Yu, Yu-Tzu, Yeh, Chun-Nan, Song, Hsiang-Lin, Chen, Chiung-Tong, Mi, Fwu-Long, Lin, Kun-Ju, and Sung, Hsing-Wen
- Subjects
- *
PACLITAXEL , *DRUG delivery systems , *PANCREATIC tumors , *MICROCARS , *PANCREATIC cancer , *DRUG bioavailability , *BIOAVAILABILITY - Abstract
The therapeutic outcome of pancreatic cancer remains unsatisfactory, despite many attempts to improve it. To address this challenge, an oral drug delivery system that spontaneously initiates an effervescent reaction to form gas-bubble carriers is proposed. These carriers concurrently deliver lipophilic paclitaxel (PTX) and hydrophilic gemcitabine (GEM) in the small intestine. The bursting of the bubbles promotes the intestinal absorption of the drugs. The antitumor efficacy of this proposed oral drug delivery system is evaluated in rats with experimentally created orthotopic pancreatic tumors. The combined administration of equivalent amounts of PTX and GEM via the intravenous (i.v.) route, which is clinically used for treating pancreatic cancer, serves as a control. Following oral administration, the lipophilic PTX is initially absorbed through the intestinal lymphatic system and then enters systemic circulation, whereas the hydrophilic GEM is directly taken up into the blood circulation, ultimately accumulating in the tumorous pancreatic tissues. A pharmacokinetic study reveals that the orally delivered formulation has none of the toxic side-effects that are associated with the i.v. injected formulation; changes the pharmacokinetic profiles of the drugs; and increases the bioavailability of PTX. The oral formulation has a greater impact than the i.v. formulation on tumor-specific stromal depletion, resulting in greater inhibition of tumor growth with no evidence of metastatic spread. As well as enhancing the therapeutic efficacy, this unique approach of oral chemotherapy has potential for use on outpatients, greatly improving their quality of life. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
44. A novel flavivirus entry inhibitor, BP34610, discovered through high-throughput screening with dengue reporter viruses.
- Author
-
Yang, Chi-Chen, Hu, Han-Shu, Lin, Hui-Mei, Wu, Pei-Shan, Wu, Ren-Huang, Tian, Jia-Ni, Wu, Szu-Huei, Tsou, Lun Kelvin, Song, Jen-Shin, Chen, Hsin-Wei, Chern, Jyh-Haur, Chen, Chiung-Tong, and Yueh, Andrew
- Subjects
- *
FLAVIVIRUSES , *DENGUE viruses , *JAPANESE encephalitis viruses , *VIRUS diseases , *VIRAL replication , *RIBAVIRIN - Abstract
Dengue virus (DENV) is a global health problem that affects approximately 3.9 billion people worldwide. Since safety concerns were raised for the only licensed vaccine, Dengvaxia, and since the present treatment is only supportive care, the development of more effective therapeutic anti-DENV agents is urgently needed. In this report, we identified a potential small-molecule inhibitor, BP34610, via cell-based high-throughput screening (HTS) of 12,000 compounds using DENV-2 reporter viruses. BP34610 reduced the virus yields of type 2 DENV-infected cells with a 50% effective concentration (EC 50) and selectivity index value of 0.48 ± 0.06 μM and 197, respectively. Without detectable cytotoxicity, the compound inhibited not only all four serotypes of DENV but also Japanese encephalitis virus (JEV). Time-of-addition experiments suggested that BP34610 may act at an early stage of DENV virus infection. Sequencing analyses of several individual clones derived from BP34610-resistant viruses revealed a consensus amino acid substitution (S397P) in the N-terminal stem region of the E protein. Introduction of S397P into the DENV reporter viruses conferred an over 14.8-fold EC 90 shift for BP34610. Importantly, the combination of BP34610 with a viral replication inhibitor, ribavirin, displayed synergistic enhancement of anti-DENV-2 activity. Our results identify an effective small-molecule inhibitor, BP34610, which likely targets the DENV E protein. BP34610 could be developed as an anti-flavivirus agent in the future. • BP34610 displayed an inhibitory effect to DNEV-1, 2, 3, 4, and JEV in vitro. • Time-of-addition experiments suggested BP34610 may affect the early stage of viral entry. • Drug resistant studies indicted BP34610 targets at DENV-2 E protein. • BP34610 displayed the synergistic effect against DENV-2 with ribavirin. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
45. S11-3 - Multifunctional nanoparticles for oral protein drug delivery.
- Author
-
Chuang, Er-Yuan, Lin, Kun-Ju, Su, Fang-Yi, Mi, Fwu-Long, Chen, Chiung-Tong, Juang, Jyuhn-Huarng, and Sung, Hsing-Wen
- Subjects
- *
TREATMENT of diabetes , *NANOMEDICINE , *DRUG delivery systems , *THERAPEUTIC use of proteins , *MOLECULAR dynamics , *LABORATORY rats - Published
- 2016
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.